Recent Trends in Cardiology

 A groundbreaking step in cardiovascular medicine emerged this quarter as the FDA awarded Fast Track designation to VERVE-102, an innovative gene-editing therapy designed to dramatically lower low-density lipoprotein cholesterol (LDL-C)—a key driver of heart disease – in patients with high cardiovascular risk. This milestone highlights the emerging power of precision genetic tools to reshape preventive cardiology. What Is VERVE-102? VERVE-102 employs CRISPR-based gene editing to modify the PCSK9 gene in liver cells. PCSK9 helps regulate LDL receptor levels. By targeting PCSK9, the therapy significantly reduces LDL-C production and circulation, addressing cholesterol at its genetic source. Preliminary trial results from the Phase 1b "Heart-2" study show near-complete elimination of LDL-C in high-risk individuals following a single dose. Why Fast Track Matters The FDA’s Fast Track designation accelerates VERVE-102’s path through clinical development and review. This beneficial ...

In a major breakthrough presented at the American College of Cardiology (ACC) annual meeting, researchers unveiled a novel drug—lepodisiran—that has shown impressive results in reducing lipoprotein(a) or Lp(a) levels by nearly 100% in clinical trials  Since elevated Lp(a) is a strong genetic risk factor for heart disease and stroke that’s resistant to lifestyle change, this development has the potential to reshape how we approach cardiovascular prevention. Involving over 300 participants across 10 countries, the trial demonstrated sustained reduction in Lp(a) following a single injection at six months, with continued effect one year later. While safety data is favorable, larger phase 3 trials are underway to determine if lowering Lp(a) actually reduces cardiovascular events like heart attacks and strokes. If validated in further studies, lepodisiran could fill a critical gap in current cardiovascular treatment—especially for individuals with genetically elevated Lp(a) who otherwise...